BioCentury
ARTICLE | Company News

Petra gains Takeda's PI3K inhibitor pipeline

March 22, 2019 5:22 PM UTC

Takeda granted Petra a license to develop, manufacture and commercialize serabelisib (TAK-117) and additional PI3Kα inhibitors.

Petra Pharma Corp. (New York, N.Y.) has rights to the inhibitors in all indications except for a set of undisclosed rare diseases, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) has already out-licensed...